IL2, interleukin 2, 3558

N. diseases: 950; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE MPA also synergies with IL-2 in clinical treatment of renal cancer. 29453736 2019
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? 28000528 2017
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE IL2 has been approved by the FDA for the treatment of patients with malignant renal cell cancer and metastatic malignant melanoma. 25736261 2015
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE The administration of IL-2 can lead to durable, complete, and apparently curative regressions in patients with metastatic melanoma and renal cancer. 24907378 2014
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Despite increasing use of "targeted therapy," interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer. 21577143 2011
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Patients with renal cancer and requiring first-line treatment for metastatic disease were randomized 1:1 to receive MVA-5T4 (TroVax(®)) or placebo alongside Sunitinib, IL-2 or IFN-α in a multicentre phase III trial. 21387109 2011
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Therapeutic disease CTD_human EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report. 18625569 2009
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Therapeutic disease CTD_human High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. 19409039 2009
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Therapeutic disease CTD_human We have treated 14 patients with either metastatic melanoma or kidney cancer, using CY 350 mg/M(2) intravenously (i.v.) over 1 hour followed by a continuous infusion IL-2 9 MIU/M(2)/24 hours for 72 hours and famotidine 20 mg i.v. twice per day. 18298334 2008
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 AlteredExpression disease BEFREE We provided novel structural and functional information on the expression of the IL-2 receptor in kidney cancer cells and in other normal and neoplastic human epithelial tissues. 17571248 2007
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Here, we studied the impact of IL-2 administration on the frequency and function of human CD4+ CD25(hi) T cells in immune intact patients with melanoma or renal cancer. 16304057 2006
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Therapeutic disease CTD_human Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. 17105418 2006
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 AlteredExpression disease BEFREE Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. 15897568 2005
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE A consecutive series of 409 patients with either metastatic melanoma or renal cancer who were treated with high-dose bolus IL-2 in the Surgery Branch, National Cancer Institute, between September 1985 and November 1996 have been analyzed with a median potential follow-up of 7.1 years. 9742914 1998
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Interleukin-2 and/or IFN-alpha gene therapy may be an effective strategy for treatment of patients with advanced renal cancer. 7521786 1994
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE Depending on the cell line and the vector construct used, lymphokine gene-modified human RC cell lines released 4 to 29 units/10(6) cells of IL-2, or up to 10 units/10(6) cells of IFN-gamma within 48 h. Fluorescence-activated cell sorter analysis of SK-RC-29 cells releasing IFN-gamma showed increased expression of major histocompatibility complex class I antigen, beta 2-microglobulin, and ICAM-1, as well as induction of major histocompatibility complex class II antigen expression [human leukocyte antigen(HLA)-DR, -DP], but no changes in these cell surface markers were observed with SK-RC-29 cells releasing IL-2. 1423266 1992
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney
0.400 Biomarker disease BEFREE We here describe the isolation, characterization, profile of lymphokine expression and T-cell-receptor gene rearrangement pattern of 444P.3, a CD3+ CD4+ CD8- 4B4+ interleukin-2 (IL-2)-dependent clone derived from the malignant ascites of a patient with renal cell cancer. 1968360 1990